Can I Take Ashwagandha with Tresiba (Insulin Degludec)?

How Tresiba Works and Why Supplements Matter

Tresiba (insulin degludec) is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours in most adults. The FDA-approved prescribing information confirms a flat, stable pharmacokinetic profile with low day-to-day variability, which is what makes it attractive for tight glycemic control.

Why the Flat Profile Creates a Specific Supplement Risk

That stability is precisely why adding a glucose-active supplement requires careful thought. With a rapid-acting insulin, a supplement-driven glucose drop often resolves before the next dose. With degludec's 42-hour action window, any additive glucose-lowering effect from a supplement compounds across an extended period rather than clearing quickly.

The ADA Standards of Medical Care in Diabetes 2024 explicitly state that clinicians should review all over-the-counter supplements with patients on insulin because "pharmacologically active components in botanical products may produce unpredictable alterations in glycemic control." This guidance applies directly to ashwagandha.

What Tresiba's Label Says About Drug and Supplement Interactions

The Tresiba prescribing information identifies several substance classes that can potentiate its glucose-lowering effect, including antidiabetic agents, salicylates, sulfonamide antibiotics, and certain herbal products. Botanical supplements with documented hypoglycemic activity fall within that warning. Prescribers and patients frequently overlook this because ashwagandha is sold without a prescription, but its glucose effects are measured in randomized controlled trials, not anecdote.

Ashwagandha's Glucose-Lowering Mechanism

Ashwagandha is not inert where blood sugar is concerned. Multiple published trials show statistically significant reductions in fasting glucose and insulin resistance markers.

AMPK Activation and Insulin Sensitization

The primary mechanism appears to be enhanced insulin receptor sensitivity through AMP-activated protein kinase (AMPK) activation. A 2015 study published in the Journal of the International Society of Sports Nutrition demonstrated that withaferin A, an active withanolide in ashwagandha root extract, activates AMPK in skeletal muscle cells. AMPK activation promotes glucose uptake independently of insulin signaling, meaning the glucose-lowering effect operates through a partially separate but overlapping pathway from exogenous insulin.

This matters because the two mechanisms do not cancel each other. They add together.

Human Trial Data on Fasting Glucose

A double-blind, randomized, placebo-controlled trial (N=64, 60 days) of ashwagandha root extract 300 mg twice daily found a mean reduction in fasting blood glucose of 13.5 mg/dL compared with placebo. The full results appear in this PubMed-indexed record. A separate 2019 pilot RCT (N=50, 8 weeks, KSM-66 extract 240 mg daily) reported reductions in fasting glucose (P<0.05) alongside significant drops in serum cortisol. Those findings are archived at PubMed PMID 31975514.

For a person taking Tresiba already titrated to target fasting glucose, a 13.5 mg/dL additional drop is clinically meaningful. Most clinicians define hypoglycemia as glucose <70 mg/dL. A patient running fasting glucose near 90 mg/dL on a dialed-in Tresiba dose could cross that threshold with consistent ashwagandha use.

Glycated Hemoglobin and Postprandial Effects

An 8-week crossover study in adults with type 2 diabetes published in Complementary Therapies in Medicine found that ashwagandha supplementation reduced HbA1c by approximately 0.5 percentage points vs placebo. While 0.5% HbA1c sounds modest, it reflects sustained glucose lowering over weeks, not acute spikes. A patient adding ashwagandha partway through a Tresiba titration cycle may see glucose readings that look like over-titration.

The Cortisol Dimension

How Cortisol Affects Insulin Sensitivity

Cortisol is a counter-regulatory hormone. High cortisol raises hepatic glucose output and reduces peripheral insulin sensitivity. This is why Cushing syndrome produces hyperglycemia and why high-dose glucocorticoid therapy reliably requires upward insulin adjustments. Ashwagandha is among the most studied adaptogens for cortisol reduction, and that reduction is now quantified.

A 60-day RCT (N=64) published in the Indian Journal of Psychological Medicine found that 300 mg of ashwagandha root extract twice daily reduced serum cortisol by 27.9% compared with placebo (P<0.0001). A 2012 trial also indexed at PubMed PMID 23439798 replicated this direction of effect.

Cortisol Reduction Plus Basal Insulin: The Compounding Problem

When cortisol falls, counter-regulatory protection against hypoglycemia weakens. A patient on Tresiba who adds ashwagandha and sees cortisol drop by roughly 28% loses part of the hormonal buffer that normally guards against insulin-induced hypoglycemia. The combination does not simply add glucose-lowering effects. It simultaneously reduces one of the body's main defenses against going too low.

This is the most underappreciated aspect of this supplement-drug pairing.

Adrenal Axis Monitoring Considerations

Patients on Tresiba who begin ashwagandha and report symptoms of fatigue, lightheadedness, or morning weakness may not be experiencing adrenal insufficiency in the clinical sense. The more common explanation is mild relative hypoglycemia driven by the cortisol-mediated mechanism above. Checking an 8 AM cortisol alongside fasting glucose at baseline and after 4 weeks of ashwagandha gives a more complete picture than glucose monitoring alone. The Endocrine Society clinical practice guideline on adrenal insufficiency provides reference ranges for morning serum cortisol that can guide interpretation.

Thyroid Effects and Insulin Clearance

Ashwagandha's Impact on Thyroid Hormones

A randomized, double-blind trial (N=50, 8 weeks) published at PubMed PMID 28829155 found that ashwagandha root extract 600 mg daily significantly increased serum T3 and T4 levels and reduced TSH in patients with subclinical hypothyroidism. T3 increased by 41.5% and T4 by 19.6% vs placebo, with TSH decreasing by 17.5%.

These are not trivial changes. Thyroid hormones directly regulate insulin clearance rates and hepatic glucose production. Elevated thyroid hormone levels accelerate insulin clearance, meaning a fixed Tresiba dose produces less glucose-lowering effect per unit as thyroid hormone rises, but this effect may be offset or outweighed by ashwagandha's direct glucose-lowering mechanisms, making the net direction unpredictable without individual glucose monitoring data.

Clinical Relevance for Tresiba Users

Patients with type 1 diabetes or type 2 diabetes who have concurrent hypothyroidism, or borderline-low thyroid function, face a more complicated picture when adding ashwagandha. A person whose Tresiba dose was set while they had subclinical hypothyroidism may need re-titration if ashwagandha normalizes their thyroid function. The American Thyroid Association guidelines note that even modest TSH changes alter insulin sensitivity in diabetic patients, supporting the case for TSH measurement before and 6 to 8 weeks after starting ashwagandha.

Checking Thyroid Labs Before Starting

Baseline TSH and free T4 before starting ashwagandha gives a clinician a reference point. If TSH drops and free T4 rises after 6 to 8 weeks, re-checking Tresiba dose requirements makes clinical sense. The test costs roughly the same as a month's supply of most ashwagandha supplements, which is worth noting when patients push back on the lab order.

Pharmacokinetic Interaction: Is There One?

Cytochrome P450 and Protein Binding

Ashwagandha withanolides show moderate CYP3A4 inhibition in in vitro studies. A review of CYP-mediated interactions indexed at PubMed PMID 35181007 identified CYP3A4 and CYP2D6 inhibitory activity for several withanolides at concentrations achievable with standard supplementation doses.

Tresiba (insulin degludec) is a protein-based drug. It does not undergo hepatic CYP metabolism. Insulin is cleared by insulin-degrading enzyme in peripheral tissues and the kidney, not by the cytochrome P450 system. The clinical conclusion: ashwagandha does not meaningfully alter Tresiba's pharmacokinetics through hepatic enzyme inhibition.

The Interaction Is Pharmacodynamic

All the clinically relevant interaction risk between ashwagandha and Tresiba is pharmacodynamic, meaning both agents lower blood glucose through separate mechanisms and those effects add together. This distinction matters for timing. Unlike drug combinations where a dose-separation window reduces plasma concentration overlap, no simple timing strategy eliminates a pharmacodynamic interaction. Taking ashwagandha in the morning and Tresiba at night does not materially reduce additive glucose-lowering because both effects persist for many hours.

Monitoring Protocol When Using Both Together

The following monitoring framework is designed for adults currently prescribed Tresiba who wish to add ashwagandha under physician supervision. It is not a substitute for individualized clinical judgment.

Before Starting Ashwagandha

• Establish a 7-day baseline glucose log: fasting, 2 hours post each main meal, and bedtime readings using calibrated SMBG.
• Draw TSH, free T4, and an 8 AM serum cortisol.
• Confirm current Tresiba dose and most recent HbA1c.
• Review any concurrent medications that lower glucose (sulfonylureas, GLP-1 receptor agonists, SGLT-2 inhibitors) because each adds independent hypoglycemia risk.

Weeks 1 Through 4

Begin ashwagandha at the lowest studied effective dose. The trials showing glucose effects used 300 mg twice daily (root extract, 5% withanolides) or 240 mg to 600 mg of KSM-66 daily. Starting at 300 mg once daily and titrating upward gives monitoring data at each step.

Increase SMBG to at least 4 checks per day during this period. Any fasting reading below 80 mg/dL on two or more consecutive days warrants a call to the prescribing physician before continuing. The ADA's hypoglycemia management guidance recommends re-evaluating basal insulin dose when fasting hypoglycemia occurs on more than two occasions in a week.

At 4 to 6 Weeks

Repeat TSH, free T4, and fasting glucose. Compare against baseline. If TSH has decreased by more than 15% from baseline or fasting glucose is trending <80 mg/dL consistently, discuss Tresiba dose reduction with the prescribing physician.

Ongoing

Review HbA1c at the next scheduled appointment. Unexplained drops in HbA1c of more than 0.5% during a period when Tresiba dose was unchanged suggest ashwagandha is producing a clinically active glucose-lowering effect that warrants a dosing conversation.

Special Populations and Additional Considerations

Type 1 Diabetes

Patients with type 1 diabetes carry greater hypoglycemia risk than most people with type 2 diabetes because they have absent endogenous insulin and often reduced or absent glucagon counter-regulatory response. A 2019 review in Diabetes Care found that hypoglycemia unawareness affects approximately 20 to 40% of adults with longstanding type 1 diabetes. In this group, any additive glucose-lowering agent, including ashwagandha, carries a higher risk of severe events. The case for pre-consultation with an endocrinologist before starting ashwagandha is strongest here.

Pregnancy and Lactation

Ashwagandha is classified as likely unsafe in pregnancy based on animal and limited human data suggesting uterotonic effects. NCBI's Drugs and Lactation Database (LactMed) notes insufficient data on ashwagandha in breastfeeding. Women with gestational or preexisting diabetes on insulin degludec should avoid ashwagandha until more data are available.

Renal Impairment

Both Tresiba's clearance and cortisol metabolism are altered in chronic kidney disease. A PubMed-indexed pharmacokinetic review of insulin degludec found that renal impairment reduced insulin clearance, increasing exposure. Patients with eGFR <60 mL/min/1.73m² on Tresiba should exercise additional caution and consult a nephrologist or endocrinologist before adding any glucose-active supplement.

Drug Interactions Beyond Insulin

Patients on Tresiba for type 2 diabetes are frequently also on metformin, SGLT-2 inhibitors, or GLP-1 receptor agonists. A 2023 systematic review in JAMA Internal Medicine noted that combination antidiabetic regimens substantially increase hypoglycemia incidence when glucose-active supplements are added without corresponding dose adjustments. Each additional glucose-lowering agent in the regimen multiplies the monitoring requirement, not just adds to it.

What to Do If You Are Already Taking Both

Some patients arrive at this question after already combining ashwagandha and Tresiba for weeks or months. The practical steps are straightforward.

Start a 5-day glucose log immediately, covering fasting, post-meal (2-hour), and bedtime readings. Look for patterns of fasting glucose consistently below 90 mg/dL or any reading below 70 mg/dL. Bring the log and your ashwagandha product label (including extract type, withanolide percentage, and daily dose) to your next clinical appointment.

The FDA guidance on dietary supplement labeling requires products to list serving size and ingredient amounts, making it feasible to identify the withanolide dose your patient is actually consuming vs what the clinical trials used.

If any hypoglycemia episodes (glucose <70 mg/dL) have already occurred, contact the prescriber before the next scheduled visit rather than waiting. Per ADA Standards of Medical Care 2024, Section 6, hypoglycemia requires same-visit management review and should prompt re-evaluation of the entire diabetes regimen.

Summary of the Interaction Profile

The interaction between ashwagandha and Tresiba is real, pharmacodynamically mediated, and supported by reproducible human trial data. The primary risk is additive glucose lowering. A 13.5 mg/dL mean fasting glucose reduction was documented in a 60-day RCT at 600 mg daily of root extract, a cortisol reduction of approximately 28% compounds the risk by weakening counter-regulatory defense, and ashwagandha-driven thyroid changes may further shift insulin sensitivity in ways that are difficult to predict without lab monitoring.

The combination is not automatically contraindicated for every patient. What it is, without exception, is a combination that requires physician awareness, baseline labs, and structured glucose monitoring before and after starting. Patients already on Tresiba who want to add ashwagandha should bring the conversation to their prescriber and arrive with a current glucose log and their supplement's exact formulation details.

The ADA's 2024 Standards define a fasting glucose target of 80 to 130 mg/dL for most non-pregnant adults with diabetes. Adding a supplement that has been shown to reduce fasting glucose by up to 13.5 mg/dL requires re-evaluating whether the current Tresiba dose still hits that window rather than overshooting below 80 mg/dL.